TRDA
Entrada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.82
+10.30%Year over year
Reported trailing growth
- Revenue
- -94.1%
- EBITDA
- -96.5%
- EBIT
- -83.6%
- EPS
- —
- Free cash flow
- -6.2%
- Operating cash flow
- -8.7%
Forward estimates
Based on analyst estimates
- Revenue
- +428.9%
- EBITDA
- +15.2%
- EPS
- +14.8%
Three-year CAGR
- Revenue
- -55.6%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026